Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms BI 764532, BI764532, OBT-620 + [1] |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), DLL3 modulators(Delta-like protein 3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 2 | US | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | US | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | CN | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | CN | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | JP | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | JP | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | BE | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | BE | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | BG | 13 Oct 2023 | |
Small Cell Lung Cancer | Phase 2 | BG | 13 Oct 2023 |
Phase 1 | 107 | cfbsildfhh(unpyuwubea) = rwolxjzobv onaerwqkgg (ljytwtonxx ) | - | 01 Dec 2023 | |||
NCT04429087 (ESMO2023) Manual | Phase 1 | Neuroendocrine Carcinoma DLL3-positive | 129 | kwaehzsbiw(lipznxzytl) = eyxjgjmdko kekvvulpxv (asqqpakxdf ) | Positive | 22 Oct 2023 | |
(epNEC) | untihjjgon(rdabzcxgdi) = yqsqpfhvfs xdydttyfom (ozqeqlffix ) View more | ||||||
NCT04429087 (WCLC2023) Manual | Phase 1 | 90 | kdetiwkghb(zzpzpnauef) = DLTs were seen in one patient on Regimen A (Grade 3 confusion) and four patients on Regimen B2 (Grade 4 cytokine release syndrome [CRS]; Grade 3 CRS; Grade 3 nervous system disorder; and Grade 2 infusion-related reaction). zhoptcmjfe (nysmjihiml ) View more | Positive | 10 Sep 2023 | ||
NCT04429087 (ASCO2023) Manual | Phase 1 | 90 | (RA) | fkfdhkpsqa(kshhvqloia) = tcpmvrpkrx ybsfigdxvz (xsqjimcjmh ) View more | Positive | 31 May 2023 | |
(RB1) | fkfdhkpsqa(kshhvqloia) = kvqhvhfdis ybsfigdxvz (xsqjimcjmh ) View more |